News & Events zu Alzamend Neuro Inc (ALZN)ALZNAlzamend Neuro Inc

Alzamend Neuro Regains Nasdaq Compliance

Alzamend Neuro announced that it has received a notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market, dated September 14, informing Alzamend that it has regained compliance with Nasdaq Listing Rule 5550(b)(1). In order to regain compliance with the Equity Rule, Alzamend needed to have a minimum stockholders' equity of $2.5M. Based on Alzamend's Quarterly Report on Form 10-Q for the quarter ended July 31, 2026, which was dated and filed with the U.S. Securities and Exchange Commission on September 10, 2026, Alzamend evidenced stockholders' equity of $5,802,680. Accordingly, in the Compliance Notice, Nasdaq stated that Alzamend complies with the Equity Rule and the matter is now closed.

Selling Stockholders Plan to Sell Up to 98.39M Shares

This filing relates to the offer and sale from time to time by the selling stockholders of up to 98.39M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Alzamend Neuro Reports Encouraging Initial Results for AL001

Alzamend Neuro announced "encouraging" pharmacodynamic findings from a brain magnetic resonance spectroscopy, or MRS, analysis conducted in six healthy human subjects in a trial conducted at Massachusetts General Hospital. The study assessed changes in five key brain metabolites across 18 brain regions when participants received two-weeks of blood bioequivalent and lithium-dose equivalent AL001 or lithium carbonate relative to baseline. Early data suggest AL001 may work like lithium carbonate by selectively impacting brain chemicals where needed, however, AL001 appears to be leaving other, healthy brain chemicals more undisturbed than lithium carbonate, a potentially meaningful tolerability advantage. These interpretations need to be further statistically confirmed in additional patient populations, the first of which is currently underway. When participants took AL001, multiple brain chemicals trended downward, while the same chemicals trended upward in those same participants when they took lithium carbonate. Keeping glutamate stable is important for long-term brain health, which suggests AL001 may have fewer side effects than lithium carbonate over time, however, this needs confirmation over a longer duration of exposure. Alzamend has identified pharmacodynamic hypotheses to be tested in future confirmatory studies involving subjects with Alzheimer's, BD, MDD and PTSD. Unlike lithium carbonate, AL001 may help preserve the health of brain cell membranes in healthy tissue, the protective outer layer of brain cells that play a critical role in how they function and communicate.